33 MIs; 33 CABG/PTCAs; 11 strokes) with a total cost saving of £332,512 (MI = £105,237; CABG/PTCA = £195,551; stroke = £31,724). CONCLUSIONS: The estimated benefit of treating to an LDL-C target of <2.0 mmol/L rather than <3.0 mmol/L was an additional 26 CV events avoided per 1000 patients with an associated cost saving of £111,799.
PCV59 INPATIENT RESOURCE USE ASSOCIATED WITH THE TREATMENT OF SECONDARY ATRIAL FIBRILLATION
Spalding JR 1 , Exuzides A 2 , Adams S 2 , Colby C 2 , Noe L 2 1 Astellas Pharma US, Deerfield, IL, USA, 2 ICON Clinical Research, San Francisco, CA, USA OBJECTIVES: We estimated incremental inpatient costs and length of stay (LOS) attributable to secondary atrial fibrillation (AF) in patients with and without cardiac predisposing factors to document the economic burden of this disease. METHODS: We extracted 2004-2005 discharges from Premier Perspective(tm), the largest hospital database in the US, with a secondary AF diagnosis and matched controls that had neither a primary nor a secondary AF diagnosis. We matched on patient age, discharge date, facility type and primary diagnosis category. We used regression models to estimate the incremental inpatient costs and LOS due to secondary AF. We adjusted for comorbidities, demographic and hospital-specific factors. We repeated this analysis for patients without cardiac predisposing factors (i.e. mitral valve disease, heart failure, non-AF cardiac operation, chest pain and congestive artery disease). RESULTS: The estimated 5.4 million secondary AF discharges in the US during 2004 and 2005 had an adjusted average inpatient cost of $12,292. This cost was $3532 more than the adjusted average inpatient cost for controls without AF (P < 0.0001). Patients with secondary AF had an adjusted average LOS of 7.8 days or 1.9 additional days compared to controls without AF (P < 0.0001). The estimated 1.4 million secondary AF discharges without cardiac predisposing factors had an adjusted average inpatient cost of $8956, an increase of $1908 compared to controls without AF or cardiac predisposing factors (P < 0.0001). Secondary AF patients without cardiac predisposing factors had an adjusted average LOS of 6.2 days or one additional day compared to controls (P < 0.0001). CONCLUSIONS: Inpatient costs and LOS were significantly higher for patients with a secondary AF discharge diagnosis when compared to controls that did not have an AF diagnosis. These differences, although still significant, were less pronounced among patients without cardiac predisposing factors. Further research is warranted to investigate how secondary AF is most cost-effectively treated.
PCV60

TWO-YEAR HOSPITALIZATION RATES AND ASSOCIATED COSTS IN PATIENTS FROM GERMANY WITH PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY
Mahoney EM 1 , Lei Y 1 , Wang K 1 , Bruggenjurgen B 2 , Mosse F 3 , Parhofer KG 4 , Zeymer U 5 , Roether J 6 1 Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO, USA, 2 Alpha Care, Celle, Germany, 3 Sanofi-Aventis, Paris, France, 4 University Munich, Munich, Germany, 5 Herzzentrum Ludwigshafen, Ludwigshafen, Germany, 6 Johannes Wesling Klinikum Minden, Minden, Germany OBJECTIVES: Atherothrombosis is the leading cause of death worldwide with huge economic burden. Peripheral arterial disease (PAD), a marker of disseminated vascular disease, puts patients at a high risk of atherothrombotic events. The REACH Registry is an international prospective registry of 67,888 patients from 44 countries at risk of atherothrombosis due to coronary artery disease (CAD), cerebrovascular disease (CVD) and/or PAD, or the presence of Ն3 atherothrombotic risk factors. PAD at enrollment was identified on the basis of current intermittent claudication with either ankle brachial index (ABI) < 0.9, or history of lower limb revascularization (angioplasty/stenting, peripheral bypass graft) or amputation. METHODS: We examined 2-year rates of vascular-related hospitalizations and associated costs in 1303 REACH patients from Germany with established PAD at baseline. Poisson regression was used to identify independent predictors of vascular hospitalizations. The costs per DRG for vascular hospitalizations were derived from the German 2004 Case Fees Catalogue. RESULTS: At baseline, mean age was 68 years, 29% female, 46% diabetes, 76% had ABI < 0.9, 56% had prior lower limb revascularization, 13% prior amputation, 63% had other involved vascular territories (479 CAD + PAD; 136 CVD + PAD; 205 CAD + CVD + PAD). There were 360 (28%) patients who had Ն1 vascular hospitalizations at 2 years. Significant (p < 0.05) independent baseline predictors of an increased hospitalization rate included diabetes, female, ABI < 0.9, prior peripheral revascularization, prior amputation, CAD, hypertension, decreasing age and prior smoking. Mean vascular hospitalization costs per patient were: €2595 overall; €3052 female/€2423 male; €3351/€1973 with/ without diabetes; €2773/€2394 with/without prior lower limb revascularization; €2787/€2578 with/without prior amputation. Abstracts A399
